You are here:
Dexamethasone: review of dexamethasone for treating adults with COVID-19 requiring respiratory support
2020.09.18
Active substance: dexamethasone
18.09.2020 - CHMP opinion
The European Medicines Agency (EMA) supports the use of dexamethasone in COVID-19 patients on oxygen or artificial respiration.
EMA’s human medicines committee (CHMP) has completed its review of results from the RECOVERY study arm that involved the use of the corticosteroid medicine dexamethasone in the treatment of patients with COVID-19 admitted to hospital, and has concluded that dexamethasone can be considered a treatment option for patients who require oxygen therapy (from supplemental oxygen to mechanical ventilation).
To the EMA press release:
24.07.2020 - Procedure started
EMA starts review of dexamethasone for treating adults with COVID-19 requiring respiratory support
EMA is reviewing results from the RECOVERY study arm that involved the use of dexamethasone in the treatment of patients with COVID-19 admitted to hospital. This part of the study looked into the effects of adding dexamethasone to usual care in adults receiving invasive ventilation, those given oxygen (e.g. through a mask) or those receiving no oxygen. Invasive ventilation involves use of a machine to push air through a tube inserted into the patient’s airway.
To the EMA press release: